Ostarine, also known as MK-2866, GTX-024, Enobosarm, and S-22, is a selective androgen receptor modulator (SARM) that has gained attention for its potential therapeutic benefits. Originally developed to treat muscle wasting conditions, Ostarine works by binding to androgen receptors in the body, which can stimulate muscle growth and improve bone density. It has been investigated for its ability to increase lean body mass and enhance physical function in clinical trials, particularly for patients with conditions like cancer cachexia and sarcopenia.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | Ostarine, ENOBOSARM, GTx-024, MK-2866 |
|---|---|
| IUPAC Name | (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide |
| CAS | 1202044-20-9 |
| Molecular Weight | 389.3 |
| Molecular Formula | C19H14F3N3O3 |
| SMILES | C[C@](COC1=CC=C(C=C1)C#N)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O |